N/A N=28 Accuracy of Methemoglobin Measurement of Various Rainbow Pulse Oximeter Sensors
Healthy
Primary: Accuracy of Methemoglobin Measurement by Arms Calculation — 0.48 percentage of total hemoglobin
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=51 Accuracy of Methemoglobin Measurement for Rainbow Universal Pulse Oximeter Sensor
Healthy
Primary: Accuracy of Sensor by Arms Calculation — 0.63 Percentage of total hemoglobin
N/A N=25 Accuracy of Methemoglobin Measurement for Rainbow DCI Sensors
Healthy
Primary: Accuracy of Sensor by Arms Calculation — 0.87 percentage
N/A N=91 Methemoglobin Levels in Generally Anesthetized Pediatric Dental Patients Receiving Local Anesthetics
Methemoglobinemia
Primary: Peak Methemoglobin Blood Levels — 3.55; 1.63; 1.60 percentage of methemoglobin in blood — p=<.001
Phase 4 N=7 MEthylene Blue In Patients With Acquired Methemoglobinemia
Acquired Methaemoglobinaemia
Primary: Primary Efficacy Endpoint: Number of Participants With and Without 50% Reduction in metHb Level — 3; 3 Participants
Phase 1 N=12 Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Following a 1 mg/kg Intravenous Dose in Healthy Adults
Methemoglobinemia · Congenital Methemoglobinemia
Primary: Area Under the Curve (AUC) From Time Zero to the Time of Last Quantifiable Concentration (AUC 0-t) — 2600.09 ng*hr/mL
Phase 2 N=18 Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis
Cystic Fibrosis
Primary: Safety and Tolerability of Drug, Assessed by Change in Methemoglobin Levels — 0.4; 0.5; 0.3; 0.3 Percent of Methemoglobin Level
Phase 4 N=19 Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients
Vasoplegic Syndrome · Liver Transplant; Complications
Primary: Systemic Vascular Resistance (SVR) — 480; 410; 588; 420 dyne*sec/cm^5
Phase 2 N=98 Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease
Mild Cognitive Impairment · MCI · Aging
Primary: fMRI Measurement — 2267.0; 1491.23; 673.31; 989.19 voxels
Phase 2 N=100 Methylene Blue Against Falciparum Malaria in Burkina Faso
Malaria, Falciparum
Primary: Change in Haemoglobin Compared to the Baseline — 0.18; 0.54 g/dl
N/A N=29 Targeting Normoxia in Neonates With Cyanotic Congenital Heart Disease in the Intra-operative and Immediate Post-operative Period
Hypoplastic Left Heart Syndrome · Total Anomalous Pulmonary Venous Return · Truncus Arteriosus
Primary: Systemic Oxidative Stress Based on Thiobarbituric Acid Reactive Substances (TBARS) — 1.21; 1.93; 1.09; 1.77 Fold Change from Baseline — p=<0.01
Phase 2 N=32 Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism
Aldehyde Dehydrogenase-2 (ALDH2) Deficiency
Primary: Number of Participants With Adverse Events (AEs), Serious AEs, and AEs Leading to Study Discontinuation — 13; 6; 8; 21 Participants
N/A N=47 Methadone in Pediatric and Adult Sickle Cell Patients
Sickle Cell Disease
Primary: To Determine the Pharmacokinetics of Methadone in Children and Adults With Sickle Cell Disease Experiencing a VOE. — 523; 0; 637; 0 (hr*ng/ml)
Phase 2 N=20 Oral Nitrite in Adults With Metabolic Syndrome and Hypertension
Metabolic Syndrome · Hypertension
Primary: Change in Insulin Stimulated Glucose Disposal Over 12 Week Study Period — 0.76 mg/kg lean body mass/minute — p=0.2068
N/A N=687 Vitamins in Nitrous Oxide Study
Major Surgery · Coronary Artery Disease
Primary: Myocardial Ischemia — 33; 34; 17; 217 Participants
N/A N=31 Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation
Respiratory Distress Syndrome in Premature Infants · Very Low Birth Weight Baby
Primary: Maximum Factional Inspired Oxygen Percent (FiO2) — 48; 39 percentage of Inspired Oxygen — p=0.0012
Phase 2 N=26 Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction
Heart Failure
Primary: Change in Pulmonary Capillary Wedge Pressure During Exercise — -1; -4 millimeters of mercury — p=0.002
N/A N=8 Transfusions and Nitric Oxide Level in Preterm Infants
Prematurity · Anemia · Necrotizing Enterocolitis
Primary: SNOHgB Levels
Phase 2 N=5 Nitrous Oxide Analgesia Vaso-occlusive Crisis
Sickle Cell Disease · Vaso-occlusive Crisis
Primary: Pain Score — 5.7 score on a scale
Phase 2 N=114 Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX
Colon Staining in Preparation for Colonoscopy
Primary: Evaluation of Mucosal Staining Efficacy — 6.8; 2.3; 8.1; 7.0 scores on a scale
Phase 2 N=28 Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction
Heart Disease · Heart Failure With Preserved Ejection Fraction · Exercise Intolerance
Primary: Exercise Pulmonary Capillary Wedge Pressure (PCWP) — 19.0; 28.0 mm Hg — p=0.0003
Phase 1 N=11 Oral Nitrite and Nitrate in Healthy Normal Volunteer Adults
Focus of Study of Healthy Adults
Primary: Peak Plasma Nitrate Concentration Over 24 Hour Study Period — 769; 41 microMolar (microM)
Phase 2 N=13 Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA
Colorectal Cancer
Primary: Gamma H2AX Histone Levels in Colonic Biopsy During Standard White Light Colonoscopy and Colonoscopy for Which Methylene Blue MMX Was Taken Prior to Initiating the…
N/A N=212 Intrapartum Maternal Oxygen Supplementation: Effects on the Mother and Neonate
Intrauterine Resuscitation
Primary: Umbilical Artery Malondialdehyde — 9.8; 10.2 umol/L
Phase 3 N=1,249 The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Colorectal Cancer
Primary: To Assess the Detection Efficacy of Chromoendoscopy Performed With 200mg Methylene Blue MMX® 25 mg Tablets Versus Placebo Tablets (White Light Endoscopy) in Terms of the…
Phase 3 N=13 Inhaled Nitric Oxide in Brain Injury
Traumatic Brain Injury
Primary: PaO2 — 115; 95 mmHg — p=<0.05
Phase 2 N=10 A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection
Nontuberculous Mycobacterium Infection
Primary: Percent Patients With Negative Sputum Culture — 40 percentage of participants
Phase 2 N=150 Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
Anemia, Sickle Cell
Primary: Time to Vaso-occlusive Pain Crisis (VOC) Resolution — 61.83; 55.16 Hours — p== 0.8085
Phase 2 N=40 Measuring the Amount of Methadone or Morphine in the Blood of Neonates, Infants & Children After Cardiac Surgery.
Pain
Primary: Maximum Concentration of Morphine Including Its Metabolites (Morphine-3-glucuronide and Morphine-6-glucuronide) — 27.55; 225; 22.95 ng/mL
Phase 3 N=165 Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis
Cirrhosis
Primary: Mortality From Liver Failure — 11 participants